This session will explore effective strategies for accelerating lead selection from a diverse panel of antibodies. Key techniques presented include proprietary methods for leveraging the unique immune system of rabbits, early epitope landscape profiling, and the use of IPA's in silico-driven humanization workflow. This approach combines thorough risk assessment, early de-risking, and high-throughput in vitro kinetic profiling, resulting in the rapid delivery of optimized antibodies ready for clinical development.